Measuring changes in FeNO using the second generation Nobreath® device before and after medication for persons with asthma and observing whether FeNO results are consistent when taken by different people

Not Applicable

Completed

• Conditions: Asthma in adult and paediatric populations; Respiratory; Asthma

• Registration Number: ISRCTN55359097
• Lead Sponsor: Bedfont® Scientific Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-04
• Study Completion: 2020-10-30
• Last Update Posted: 24 January 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 186

Inclusion Criteria

1. Aged 7 years or above
2. If on allergy immunotherapy treatment this must be a stable regimen during the study
3. Be capable of producing valid FeNO measurements via the NObreath®
4. Be capable of performing spirometry in accordance with ATS/ERS criteria

Exclusion Criteria

1. Hospitalisation related to asthma in the past 6 months
2. Use of oral corticosteroid in the 4 weeks prior to visit 1
3. Use of biological therapies e.g. mepolizumab in 12 weeks prior to visit 1
4. Other respiratory diseases e.g. COPD or cystic fibrosis
5. Known intolerance to inhaled corticosteroids or salbutamol
6. Cardiovascular conditions:
6.1. Coronary artery disease
6.2. High blood pressure
6.3. Heart failure
6.4. Diagnosed abnormality of heart rhythm
7. A smoking history of >10 packs per year
8. Pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified